EUVIMEDEUVIMED entdecken
Crossref

Evaluating the role of level 3 axillary lymph node dissection in metastatic melanoma: Can we predict involvement?

Lily M Parker, Kate E Beekman, Danielle K DePalo, Kelly M Elleson, Jonathan S Zager

Journal of Surgical Oncology · 2024

DOI: 10.1002/jso.27664 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Surgical Oncology, 2024. Verfasst von Lily M Parker und 4 weiteren Autor:innen. Beteiligte Einrichtung: USF Health, Morsani College of Medicine, Tampa, Florida, USA. Hauptthemen laut MEDLINE: Melanoma, Lymph Node Excision, Axilla, Skin Neoplasms. Die Arbeit nennt 12 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objectives MSLT‐2 and DECOG‐SLT established that immediate complete axillary lymph node dissection (CLND) did not correlate with an increase in melanoma‐specific survival when compared with active ultrasound observation in patients with sentinel lymph node (SLN)‐positive disease. After those trials, there was a shift toward performing CLND only for clinically node‐positive disease. With these changes, we sought to determine the role of level III axillary lymph nodes in bulky disease and how the use of neoadjuvant therapy may impact the rate of positivity in level III axillary nodes.

Methods

We performed a retrospective chart review on all patients who underwent axillary CLND for cutaneous melanoma by one surgeon at an academic center from 2014 to 2022. These patients underwent CLND based on either having SLN+ disease or having clinically palpable or radiographically bulky disease.

Results

Of 95 patients included, there were 7 (7.3%) patients with level III positivity. One was SLN+ (1.0%), while 3 (3.1%) had bulky disease and neoadjuvant therapy, and 3 (3.1%) had bulky disease without neoadjuvant therapy. No preoperative factors were identified that predicted level III involvement. After performing CLND, the patients who had clinically palpable or radiographically bulky disease and neoadjuvant therapy had higher percent necrosis of nodes in levels I and II but not III. At 5 years, overall survival and recurrence‐free survival were improved in those without level III involvement (58% and 64%, respectively) when compared to those with level III involvement (41% and 50%), though this was not statistically significant.

Conclusions

Further study may identify better prognostic factors for level III positivity, allowing for the possibility of dissecting only levels I and II or even replacing CLND with targeted node dissections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaLymph Node ExcisionAxillaSkin NeoplasmsLymphatic MetastasisHumansRetrospective StudiesFemaleMaleMiddle AgedAgedAdultNeoadjuvant TherapySentinel Lymph Node BiopsyLymph NodesFollow-Up Studies

Stichwörter der Autor:innen

axillary lymph node dissectioncomplete lymph node dissectionindex lymph nodeslevel III lymph nodesmelanoma

Autor:innen und Institutionen

  • USF Health, Morsani College of Medicine, Tampa, Florida, USA.
  • Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida, USA.

Zitieren

APA

Parker, L. M., Beekman, K. E., DePalo, D. K., Elleson, K. M., & Zager, J. S. (2024). Evaluating the role of level 3 axillary lymph node dissection in metastatic melanoma: Can we predict involvement?. Journal of Surgical Oncology. https://doi.org/10.1002/jso.27664

Vancouver

Parker LM, Beekman KE, DePalo DK, Elleson KM, Zager JS. Evaluating the role of level 3 axillary lymph node dissection in metastatic melanoma: Can we predict involvement?. Journal of Surgical Oncology. 2024. doi:10.1002/jso.27664

BibTeX
@article{Parker2024,
  author = {Parker, Lily M and Beekman, Kate E and DePalo, Danielle K and Elleson, Kelly M and Zager, Jonathan S},
  title = {Evaluating the role of level 3 axillary lymph node dissection in metastatic melanoma: Can we predict involvement?},
  journal = {Journal of Surgical Oncology},
  year = {2024},
  doi = {10.1002/jso.27664}
}
Kostenlos starten →